Browse by Audience
Skip to content
Papers of the Week
Mesalazine-induced myopericarditis: a case report.
Authors
PMID: 33738396.
Abstract
Mesalazine is a well-established 1st line treatment for inflammatory bowel disease (IBD). Cardiotoxicity following 5-aminosalicyclic-acid therapy remains a rare yet serious complication and can often be challenging to distinguish from myocarditis presenting as an extra-intestinal manifestation of IBD.